Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients

Masami Tanaka, Risa Nishimura, Takeshi Nishimura, Toshihide Kawai, Shu Meguro, Junichiro Irie, Yoshifumi Saisho, Hiroshi Itoh

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative stress. Objective. The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes. Methods. This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months, and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a questionnaire at 6 months. Results: MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at 12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and baPWV were significantly decreased. The results of the questionnaire showed that 93% of patients were satisfied with this medication. No severe adverse event was observed. Conclusion: This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients. The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to improve medication adherence.

Original languageEnglish
Article number56
JournalDiabetology and Metabolic Syndrome
Volume6
Issue number1
DOIs
Publication statusPublished - 2014 May 18

Fingerprint

Medication Adherence
LDL Lipoproteins
Tablets
Oxidative Stress
Malondialdehyde
Blood Pressure
Lipids
Adiponectin
Amlodipine
Dyslipidemias
Human Body
Type 2 Diabetes Mellitus
Albumins
Creatinine
Atherosclerosis
atorvastatin drug combination amlodipine
Hypertension
Kidney
Liver
Pharmaceutical Preparations

Keywords

  • Amlodipine
  • Atherosclerosis
  • Atorvastatin
  • Combination tablet
  • Diabetes mellitus
  • Dyslipidemia
  • Hypertension
  • Malondialdehyde-modified low-density lipoprotein
  • Medication adherence
  • Oxidative stress

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{cf2c61d945cc4a66aa920a460c313d6d,
title = "Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients",
abstract = "Background: Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative stress. Objective. The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes. Methods. This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months, and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a questionnaire at 6 months. Results: MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at 12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and baPWV were significantly decreased. The results of the questionnaire showed that 93{\%} of patients were satisfied with this medication. No severe adverse event was observed. Conclusion: This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients. The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to improve medication adherence.",
keywords = "Amlodipine, Atherosclerosis, Atorvastatin, Combination tablet, Diabetes mellitus, Dyslipidemia, Hypertension, Malondialdehyde-modified low-density lipoprotein, Medication adherence, Oxidative stress",
author = "Masami Tanaka and Risa Nishimura and Takeshi Nishimura and Toshihide Kawai and Shu Meguro and Junichiro Irie and Yoshifumi Saisho and Hiroshi Itoh",
year = "2014",
month = "5",
day = "18",
doi = "10.1186/1758-5996-6-56",
language = "English",
volume = "6",
journal = "Diabetology and Metabolic Syndrome",
issn = "1758-5996",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients

AU - Tanaka, Masami

AU - Nishimura, Risa

AU - Nishimura, Takeshi

AU - Kawai, Toshihide

AU - Meguro, Shu

AU - Irie, Junichiro

AU - Saisho, Yoshifumi

AU - Itoh, Hiroshi

PY - 2014/5/18

Y1 - 2014/5/18

N2 - Background: Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative stress. Objective. The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes. Methods. This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months, and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a questionnaire at 6 months. Results: MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at 12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and baPWV were significantly decreased. The results of the questionnaire showed that 93% of patients were satisfied with this medication. No severe adverse event was observed. Conclusion: This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients. The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to improve medication adherence.

AB - Background: Oxidized low-density lipoprotein (LDL) plays central roles in the formation and progression of atherosclerotic lesions. Malondialdehyde (MDA)-modified LDL (MDA-LDL) is speculated to be generated as a result of oxidative stress in the human body. Because both amlodipine and atorvastatin have been reported to reduce oxidative stress, it is expected that both drugs would have a favorable influence to reduce oxidative stress. Objective. The objective of this study was to investigate the effects of a single pill of amlodipine (5 mg)/atorvastatin (10 mg) on oxidative stress, blood pressure/lipid control and adherence to medication in patients with type 2 diabetes. Methods. This combination tablet was administered to 29 patients (16 male), and MDA-LDL, blood pressure, lipid profile, renal/liver function, CPK, hs-CRP, adiponectin, BNP, and HbA1c were measured at baseline, 6, and 12 months, and baPWV and mean IMT were measured at baseline and 12 months. Medication adherence was examined using a questionnaire at 6 months. Results: MDA-LDL was decreased significantly. LDL-C, TG, and Cr were significantly decreased at 6 and 12 months compared with baseline. eGFR was increased at 6 months, and urinary albumin/creatinine ratio was decreased at 12 months. BNP was decreased at 6 and 12 months, and adiponectin was increased at 12 months. Both mean IMT and baPWV were significantly decreased. The results of the questionnaire showed that 93% of patients were satisfied with this medication. No severe adverse event was observed. Conclusion: This combination tablet controlled both hypertension and dyslipidemia well in type 2 diabetic patients. The deceases in mean IMT and baPWV might suggest the improvement of atherosclerosis by this medication, which could be caused by the reduction of oxidative stress measured by MDA-LDL. In addition, this medication is expected to improve medication adherence.

KW - Amlodipine

KW - Atherosclerosis

KW - Atorvastatin

KW - Combination tablet

KW - Diabetes mellitus

KW - Dyslipidemia

KW - Hypertension

KW - Malondialdehyde-modified low-density lipoprotein

KW - Medication adherence

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=84901636492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901636492&partnerID=8YFLogxK

U2 - 10.1186/1758-5996-6-56

DO - 10.1186/1758-5996-6-56

M3 - Article

VL - 6

JO - Diabetology and Metabolic Syndrome

JF - Diabetology and Metabolic Syndrome

SN - 1758-5996

IS - 1

M1 - 56

ER -